G-CSF May Improve Outcomes of Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine

Researchers from Japan have reported that G-CSF (filgrastim, Kirin-Sankyo or lenograstim, Chugai) may improve outcomes of patients with aplastic anemia treated with ATG (anti-thymocyte globulin) and cyclosporine. The details of this study were published on-line in Blood on May 25, 2007.

The current treatment of choice for patients with aplastic anemia is ATG plus cyclosporine. The role of hematopoetic growth factors in this disease has not been established.

The current study involved 101 previously untreated patients with severe aplastic. Nintey-nine percent were idiopathic and 3 were associated with hepatitis B. The median age was 54 years with the oldest patient being 75 and the youngest being 19 years of age. Patients were randomly allocated to receive ATG and cyclosporine with or without G-CSF. G-CSF was administered for 84 days.

No G-CSF

G-CSF

Number of Patients

47

48

Hematologic Response 3 months

51%

58%

Hematologic Response 6 months

77%

57%

Survival at 4 years

88%

94%

Relapse Rate at 4 years

42%

15%

AML or MDS

1 patient

2 patients

Receive a FREE
Aplastic Anemia
Info Packet








Diagnosed with or have  







For a free info booklet which contains Cancer Hospital Locations, Clinical Trials Hazardous Jobs/ Products, New Treatment Options, Doctors, Financial Assistance , complete the form above or call 1-800-791-5607